FDA Calendar October 2026: Key PDUFA Dates and Insights

This October, we're tracking five pivotal PDUFA dates that could change the game in their respective fields. The spotlight is on October 26, 2026, when the FDA will decide on bepirovirsen, a groundbreaking therapy for chronic hepatitis B. With an 85% chance of approval, the stakes for this drug are high.

The full October 2026 PDUFA calendar

Bepirovirsen: A Game Changer for Chronic Hepatitis B

Bepirovirsen (IONIS-HBVRx), from Ionis Pharmaceuticals and marketed by GSK, is up for a crucial FDA decision on October 26, 2026. As the first antisense oligonucleotide for chronic hepatitis B (CHB), it aims for a functional cure, something existing treatments rarely achieve. The CHB therapeutics market is significant, expected to hit $13.5 billion in 2024, highlighting the demand for effective solutions. Bepirovirsen's trials have been promising, showing major improvements in hepatitis B surface antigen loss and undetectable HBV DNA levels. In the Phase III B-Well trials, patients receiving bepirovirsen with standard nucleos(t)ide analogues (NAs) had higher functional cure rates compared to those on NAs alone. This is notable, considering current cure rates are under 3%. The 85% approval probability is supported by strong efficacy and a good safety profile. However, the FDA's focus on long-term safety and immune-mediated events could be challenging. Investors should watch the October 26 decision closely, as approval would mark a major milestone for CHB treatment and for Ionis and GSK.

Phentolamine: Addressing the Unmet Need in Presbyopia

Phentolamine ophthalmic solution 0.75% (Ryzumvi) is heading for FDA review on October 17, 2026, as a new presbyopia treatment. With an 83% approval probability, this first-in-class option could fill a crucial gap in the presbyopia market, which might reach $15 billion globally. Current solutions like reading glasses or multifocal lenses have limitations, making phentolamine's non-invasive approach appealing. The Phase 3 VEGA trials showed positive outcomes, with participants seeing significant near visual acuity improvements without serious side effects. This strong safety profile, along with the lack of competing approved presbyopia therapies, positions phentolamine well for approval. Risks include potential post-marketing safety signals and challenges in commercial execution. Investors should be ready for the October 17 decision, as it could transform treatment options for this widespread condition.

INO-3107: A Novel Approach to Recurrent Respiratory Papillomatosis

INO-3107, from INOVIO Pharmaceuticals, is set for FDA review on October 30, 2026, with an approval probability between 65% and 75%. This DNA immunotherapy targets recurrent respiratory papillomatosis (RRP) by boosting antigen-specific T-cell responses against HPV-6 and HPV-11, the primary causes of the disease. RRP has long lacked effective non-surgical treatments, making INO-3107's potential approval vital for patients who often endure multiple surgeries each year. The Phase 1/2 trial showed an 81.3% reduction in surgeries, with lasting responses. While INO-3107 trails Papzimeos in complete response rates, its unique mechanism sets it apart. Regulatory designations like Orphan Drug and Breakthrough Therapy strengthen its approval case, though concerns about efficacy compared to Papzimeos and the need for confirmatory data could be hurdles. Investors should focus on the October 30 decision, as it could lead to the first DNA medicine approved for RRP.

Ifinatamab Deruxtecan: A New Hope for Small Cell Lung Cancer

On October 10, 2026, the FDA will decide on ifinatamab deruxtecan, a novel treatment for extensive-stage small cell lung cancer (ES-SCLC) in patients who have relapsed after platinum-based chemotherapy. Developed by Merck (MRK), this drug is in the spotlight for potentially addressing a major unmet need in a patient group with limited options. The approval probability is high, reflecting promising clinical trial data. Ifinatamab deruxtecan employs a unique mechanism that targets cancer cells more effectively, potentially leading to better outcomes. As the FDA evaluates the submission, the focus will be on the drug's efficacy and safety profile in a challenging treatment environment. Investors should pay attention to the October 10 decision, as it could significantly influence treatment protocols for ES-SCLC.

Market Dynamics and Implications of Upcoming FDA Decisions

The FDA calendar for October 2026 features several high-stakes PDUFA dates that could reshape their markets. With bepirovirsen, phentolamine, INO-3107, and ifinatamab deruxtecan all seeking approval, the impact on both investors and patients will be significant. Each drug addresses major unmet needs in its field, from chronic hepatitis B to presbyopia and recurrent respiratory papillomatosis. The competitive landscape is changing, with existing therapies challenged by these newcomers. For investors, understanding approval probabilities and associated risks is crucial. Successful approvals could open substantial market opportunities and lead to company revaluation. As these critical dates approach, monitoring insider activity and market trends will help gauge potential impacts on stock performance.

Risks and Considerations for Investors

Investing in biotech carries inherent risks, especially with pivotal FDA decisions looming in October. Each drug under review faces unique challenges that could affect approval outcomes. While bepirovirsen shows promise for chronic hepatitis B, the FDA's scrutiny of its long-term safety profile could be a hurdle. INO-3107 faces competition from Papzimeos, which might influence its approval chances. Phentolamine's entry into the presbyopia market is promising, but potential post-marketing safety signals could cause uncertainty. Investors need to weigh these risks against high approval probabilities. Market dynamics can shift quickly, driven by competitive responses, regulatory feedback, and evolving treatment paradigms. Maintaining a diversified investment strategy while watching these key catalysts is essential for navigating this complex landscape.

The bottom line

These PDUFA dates in October 2026 will be pivotal for investors and the biotech landscape, warranting close attention.